1.Lorincz, MT.Neurologic Wilson’s disease. Ann NY Acad Sci. 2010;1184:173–87.
2.Purchase, R.The treatment of Wilson’s disease, a rare genetic disorder of copper metabolism. Sci Prog. 2013;96(Pt 1):19–32.
3.Aggarwal, A, Aggarwal, N, Nagral, A, Jankharia, G, Bhatt, M.A novel Global Assessment Scale for Wilson’s Disease (GAS for WD). Mov Disord. 2009;24(4):509–18.
4.Burke, R, Fahn, S, Marsden, CD, Bressman, S, Moskowitz, C, Friedman, J.Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985;35(1):73–7.
5.Paliwal, VK, Gupta, PK, Pradhan, S.Gabapentin as a rescue drug in D-penicillamine–induced status dystonicus in patients with Wilson disease. Neurol India. 2010;58(5):761–3.
6.Fink, K, Meder, W, Dooley, DJ, Göthert, M.Inibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol. 2000;130(4):900–6.
7.Linazasoro Cristóbal, G.Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: a pilot study. Rev Neurol. 2001;33(5):408–10.
8.Pina, MA, Modrego, PJ.Dystonia induced by gabapentin. Ann Pharmacother. 2005;39(2):380–2.